Retrospective analysis of 235 unselected patients with mantle
cell lymphoma confirms prognostic relevance of Mantle Cell
Lymphoma International Prognostic Index and Ki-67 in the era of
rituximab: long-term data from the Czech Lymphoma Project
Database

J 2014

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER et. al.

Základní údaje

Originální název

Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database

Autoři

ŠÁLEK, David (203 Česká republika, garant), Pavla VESELÁ (203 Česká republika), Ludmila BOUDOVÁ (203 Česká republika), Andrea JANÍKOVÁ (203 Česká republika, domácí), Pavel KLENER (203 Česká republika), Samuel VOKURKA (203 Česká republika), Milada JANKOVSKA (203 Česká republika), Robert PYTLIK (203 Česká republika), David BELADA (203 Česká republika), Jan PIRNOS (203 Česká republika), Mojmír MOULIS (203 Česká republika, domácí), Roman KODET (203 Česká republika), Michal MICHAL (203 Česká republika), Eva JANOUŠOVÁ (203 Česká republika, domácí), Jan MUŽÍK (203 Česká republika, domácí), Jiří MAYER (203 Česká republika, domácí) a Marek TRNĚNÝ (203 Česká republika)

Vydání

Leukemia & lymphoma, London, Informa Healthcare, 2014, 1042-8194

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.891

Kód RIV

RIV/00216224:14110/14:00074886

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.3109/10428194.2013.815349

UT WoS

000333582600013

Klíčová slova anglicky

Mantle cell lymphoma; MIPI; Ki-67; proliferation; immunochemotherapy; prognosis

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 28. 5. 2014 15:06, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.

Citovat

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER, Samuel VOKURKA, Milada JANKOVSKA, Robert PYTLIK, David BELADA, Jan PIRNOS, Mojmír MOULIS, Roman KODET, Michal MICHAL, Eva JANOUŠOVÁ, Jan MUŽÍK, Jiří MAYER a Marek TRNĚNÝ. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. Leukemia & lymphoma. London: Informa Healthcare, 2014, roč. 55, č. 4, s. 802-810. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.815349.

@article{1139282,
   author = {Šálek, David and Veselá, Pavla and Boudová, Ludmila and Janíková, Andrea and Klener, Pavel and Vokurka, Samuel and Jankovska, Milada and Pytlik, Robert and Belada, David and Pirnos, Jan and Moulis, Mojmír and Kodet, Roman and Michal, Michal and Janoušová, Eva and Mužík, Jan and Mayer, Jiří and Trněný, Marek},
   article_location = {London},
   article_number = {4},
   doi = {http://dx.doi.org/10.3109/10428194.2013.815349},
   keywords = {Mantle cell lymphoma; MIPI; Ki-67; proliferation; immunochemotherapy; prognosis},
   language = {eng},
   issn = {1042-8194},
   journal = {Leukemia & lymphoma},
   title = {Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database},
   volume = {55},
   year = {2014}
}

TY  - JOUR
ID  - 1139282
AU  - Šálek, David - Veselá, Pavla - Boudová, Ludmila - Janíková, Andrea - Klener, Pavel - Vokurka, Samuel - Jankovska, Milada - Pytlik, Robert - Belada, David - Pirnos, Jan - Moulis, Mojmír - Kodet, Roman - Michal, Michal - Janoušová, Eva - Mužík, Jan - Mayer, Jiří - Trněný, Marek
PY  - 2014
TI  - Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database
JF  - Leukemia & lymphoma
VL  - 55
IS  - 4
SP  - 802-810
EP  - 802-810
PB  - Informa Healthcare
SN  - 10428194
KW  - Mantle cell lymphoma
KW  - MIPI
KW  - Ki-67
KW  - proliferation
KW  - immunochemotherapy
KW  - prognosis
N2  - Although a prognostic model (MIPI, Mantle Cell Lymphoma International Prognostic Index) for patients with mantle cell lymphoma (MCL) has been established, its clinical significance for daily practice in the rituximab era remains controversial. Data of 235 unselected patients with MCL from the Czech Lymphoma Project Database were analyzed. MIPI, simplified MIPI (s-MIPI) and Ki-67 proliferation index were assessed for all patients and for a subgroup of 155 rituximab-treated (RT) patients. MIPI divided all patients into subgroups of low-risk (22%), intermediate-risk (29%) and high-risk (49%), with median overall survival 105.8 vs. 54.1 vs. 24.6 months, respectively (p < 0.001). s-MIPI revealed similar results. The validity of both indexes was confirmed in RT patients. We confirmed the Ki-67 index to be a powerful single prognostic factor for overall survival (64.4 vs. 20.1 months, p < 0.001) for all patients and for the RT subset. Our results confirm the clinical relevance of MIPI, s-MIPI and Ki-67 for risk stratification in MCL also in the rituximab era.
ER  -

ŠÁLEK, David, Pavla VESELÁ, Ludmila BOUDOVÁ, Andrea JANÍKOVÁ, Pavel KLENER, Samuel VOKURKA, Milada JANKOVSKA, Robert PYTLIK, David BELADA, Jan PIRNOS, Mojmír MOULIS, Roman KODET, Michal MICHAL, Eva JANOUŠOVÁ, Jan MUŽÍK, Jiří MAYER a Marek TRNĚNÝ. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. \textit{Leukemia \&{} lymphoma}. London: Informa Healthcare, 2014, roč.~55, č.~4, s.~802-810. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2013.815349.

Podrobný výpis o publikaci